The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Author:

Moorkens Evelien,Godman Brian,Huys Isabelle,Hoxha Iris,Malaj Admir,Keuerleber Simon,Stockinger Silvia,Mörtenhuber Sarah,Dimitrova Maria,Tachkov Konstantin,Vončina Luka,Palčevski Vera Vlahović,Achniotou Gnosia,Slabý Juraj,Popelková Leona,Kohoutová Kateřina,Bartels Dorthe,Laius Ott,Martikainen Jaana E.,Selke Gisbert W.,Kourafalos Vasileios,Magnússon Einar,Einarsdóttir Rannveig,Adams Roisín,Joppi Roberta,Allocati Eleonora,Jakupi Arianit,Viksna Anita,Greičiūtė-Kuprijanov Ieva,Vella Bonanno Patricia,Suttorp Vincent,Melien Øyvind,Plisko Robert,Mardare Ileana,Meshkov Dmitry,Novakovic Tanja,Fürst Jurij,Zara Corinne,Marković-Peković Vanda,Grubiša Nataša,Befrits Gustaf,Puckett Robert,Vulto Arnold G.

Abstract

Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this paper is to provide a European overview of (list) prices of originator adalimumab, before and after loss of exclusivity; to report changes in the reimbursement status of adalimumab products; and discuss relevant policy measures.Methods: Experts in European countries received a survey consisting of three parts: 1) general financing/co-payment of medicines, 2) reimbursement status and prices of originator adalimumab, and availability of biosimilars, and 3) policy measures related to the use of adalimumab.Results: In May 2019, adalimumab biosimilars were available in 24 of the 30 countries surveyed. Following introduction of adalimumab biosimilars, a number of countries have made changes in relation to the reimbursement status of adalimumab products. Originator adalimumab list prices varied between countries by a factor of 2.8 before and 4.1 after loss of exclusivity. Overall, list prices of originator adalimumab decreased after loss of exclusivity, although for 13 countries list prices were unchanged. When reported, discounts/rebates on originator adalimumab after loss of exclusivity ranged from 0% to approximately 26% (Romania), 60% (Poland), 80% (Denmark, Italy, Norway), and 80–90% (Netherlands), leading to actual prices per pen or syringe between €412 (Finland) and €50 – €99 (Netherlands). To leverage competition following entry of biosimilar adalimumab, only a few countries adopted measures specifically for adalimumab in addition to general policies regarding biosimilars. In some countries, a strategy was implemented even before loss of exclusivity (Denmark, Scotland), while others did not report specific measures.Conclusion: Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries.

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference65 articles.

1. AbbVie announces global resolution of HUMIRA® (adalimumab) patent disputes with Sandoz,2018

2. AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent litigation with Boehringer Ingelheim,2019

3. AbbVie reports full-year and fourth-quarter 2018 financial results,2019

4. New international record for switch to biosimilar,2019

5. What lessons can be learned from the launch of generic clopidogrel?;Baumgärtel;GaBI J.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3